Overview
Find detailed information selected clinical trials for Ewing's Sarcoma at Cincinnati Children's Hospital Medical Center.
There are two versions of some of the trials. While they contain the same basic information, one version is geared toward healthcare professionals and the other is geared toward families.
| Trial | Healthcare
Professional
Version | Family-Friendly Version |
|---|
| ADVL0612: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors | Professional | Family-Friendly |
| NCI-07-C-0040: A Phase I Trial of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors | Professional | Family-Friendly |
| ADVL0413: Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children with Refractory Solid Tumors or Refractory Leukemias | Professional | Family-Friendly |
| ADVL0525: A Phase II Study of Pemetrexed Disodium in Young Patients With Relapsed or Refractory Solid Tumors | Professional | |
| ADVL0221: A Phase II Study of Trabectedin (ET-743, Yondelis® ) in Children with Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Non-rhabdomyosarcomatous Soft Tissue Sarcomas | Professional | |
| AEWS07P1: A Pilot Study of Chemotherapy Intensification by adding Vincristine, Topotecan and Cyclophosphamide to Standard Chemotherapy Agents with an Interval Compression Schedule in Newly Diagnosed Patients with Localized Ewing Sarcoma Family of Tumors | Professional | |
| AEWS0521: A Randomized Phase II Study of Bevacizumab Combined with Vincristine, Topotecan and Cyclophosphamide in Patients with First Recurrent Ewing Sarcoma | Professional | |
